<DOC>
	<DOC>NCT01790828</DOC>
	<brief_summary>This study is to describe the safety and efficacy of Xyntha® during the usual care setting.</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A</brief_title>
	<detailed_description>non probability sample</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients or legally authorized representatives of pediatric patients agree to provide written informed consent form (data privacy statement). Pediatric and adult patients who have been treated with Xyntha for Hemophilia A from first approved date by KFDA, or who are planned to be newly prescribed Xyntha. Patients with a known history of hypersensitivity to original or reformulated Xyntha or any component of the product. Patients with a known history of hypersensitivity to hamster protein. Patients participating in an interventional trial of any investigational drug or device.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>